Up next

Biomanufacturing: How are Industry Capacity & Supply Chains Trending?

What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains.

Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates
Eric Langer, MBA, Managing Partner & President, BioPlan Associates

Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

What’s Trending: ADCs: Pipelines, Products & CDMO Growth 

By
Sponsored by Lonza AG Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are…

Drug Launches & Approvals in 2025: The Blockbuster Contenders

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 

By
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important…